Influenza vaccine effectiveness against A(H3N2) during the delayed 2021/22 epidemic in Canada

Influenza vaccine effectiveness against A(H3N2) during the delayed 2021/22 epidemic in Canada

Influenza virus circulation virtually ceased in Canada during the COVID-19 pandemic, re-emerging with the relaxation of restrictions in spring 2022. Using a test-negative design, the Canadian Sentinel Practitioner Surveillance Network reports 2021/22 vaccine effectiveness of 36% (95% CI: −38 to 71)...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Euro surveillance : bulletin européen sur les maladies transmissibles 2022-09, Vol.27 (38), p.1
Hauptverfasser: Kim, Shinhye, Chuang, Erica SY, Sabaiduc, Suzana, Olsha, Romy, Kaweski, Samantha E, Zelyas, Nathan, Gubbay, Jonathan B, Jassem, Agatha N, Charest, Hugues, De Serres, Gaston, Dickinson, James A, Skowronski, Danuta M
Format: Artikel
Sprache:eng
Schlagworte:
COVID-19
Epidemics
Immunization
Influenza
Vaccines
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Influenza virus circulation virtually ceased in Canada during the COVID-19 pandemic, re-emerging with the relaxation of restrictions in spring 2022. Using a test-negative design, the Canadian Sentinel Practitioner Surveillance Network reports 2021/22 vaccine effectiveness of 36% (95% CI: −38 to 71) against late-season illness due to influenza A(H3N2) clade 3C.2a1b.2a.2 viruses, considered antigenically distinct from the 3C.2a1b.2a.1 vaccine strain. Findings reinforce the World Health Organization’s decision to update the 2022/23 northern hemisphere vaccine to a more representative A(H3N2) clade 3C.2a1b.2a.2 strain.
ISSN:1560-7917
1025-496X
1560-7917
DOI:10.2807/1560-7917.ES.2022.27.38.2200720